Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06485089 · ClinicalTrials.gov registry record
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
A clinical trial of Obesity and Breast Cancer Risk, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT06485089: Active study of Obesity and Breast Cancer Risk, sponsored by University of Kansas Medical Center.
NCT06485089 is a study of Obesity and Breast Cancer Risk that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06485089, a study of Obesity and Breast Cancer Risk, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Primary Outcome
Accrual defined as signed consent and ompleting baseline proceedures
Conditions Studied
Interventions
- DRUG tirzepatide
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Medical Center Breast Cancer Prevention Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-14 |
| Est. Completion | 2026-04 |
What the registry record for NCT06485089 still lists
NCT06485089 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which tirzepatide is the first listed.
NCT06485089 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06485089 about?
NCT06485089 is a clinical study titled "Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers". Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
What is the current status of trial NCT06485089?
This trial is currently active not recruiting. The enrollment target is 20 participants. The study started on 2024-09-14. Estimated completion is 2026-04.
What conditions does trial NCT06485089 study?
This clinical trial studies the following conditions: Obesity, Breast Cancer Risk.
What interventions are being tested in trial NCT06485089?
The interventions under investigation include: tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06485089?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06485089 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06485089's enrollment target sits among peer trials
20 946th of 1053 higher than 80 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI